Rock Springs Capital Management LP

Position in ELVN — Enliven Therapeutics, Inc.

CIK 1595725 Baltimore, MD

Position in ELVN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$23,579,718

-$8,819,082 QoQ

Shares Held

464,625

-43.8% QoQ

Ownership

0.634%

of shares outstanding

% of Portfolio

1.15%

of 13F equity value

Holder Rank

#37

of 210 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Rock Springs Capital Management LP holds $1,502,002,537 across 70 Biotechnology names. ELVN ranks #16 (1.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	1,105,210	$206,983,728
2	TVTX	Travere Therapeutics, Inc.	2,179,069	$123,792,909
3	MDGL	Madrigal Pharmaceuticals, Inc.	174,999	$93,965,713
4	MIRM	Mirum Pharmaceuticals, Inc.	798,145	$93,438,835
5	RYTM	Rhythm Pharmaceuticals, Inc.	692,598	$76,899,155
6	KYMR	Kymera Therapeutics, Inc.	453,156	$51,963,398
7	ARGX	Argenx SE	52,750	$48,939,867
8	ASND	Ascendis Pharma A/S	168,750	$45,009,000

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$23,579,718	464,625	-43.8%	Shares	Sole	2026-08-14
2026-03-31	$32,398,800	826,500	+3.5%	Shares	Sole	2026-05-15
2025-12-31	$12,295,437	798,405	+16.4%	Shares	Sole	2026-02-17
2025-09-30	$14,044,610	686,107	-2.2%	Shares	Sole	2025-11-14
2025-06-30	$14,070,244	701,408	+50.6%	Shares	Sole	2025-08-14
2025-03-31	$9,168,341	465,871	+8.7%	Shares	Sole	2025-05-15
2024-12-31	$9,642,847	428,571	0.0%	Shares	Sole	2025-02-14
2024-09-30	$10,945,703	428,571	0.0%	Shares	Sole	2024-11-14
2024-06-30	$10,015,704	428,571	0.0%	Shares	Sole	2024-08-14
2024-03-31	$7,538,563	428,571	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.